Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AAN 2023 and Multiple Sclerosis And Related Disorders View overview page

2:12
Chronic inflammation in MS
Augusto Miravalle • 5 May 2023
1:31
Health disparities in MS: experiences and perspectives of patients
Mitzi Joi Williams • 22 May 2023
2:19
Understanding of the early disease processes in MS
Augusto Miravalle • 5 May 2023
1:48
mAbs in MS: where do they fit into the pathophysiology of MS?
Augusto Miravalle • 5 May 2023
1:07
Considerations for diverse MS care and research from registries
Mitzi Joi Williams • 22 May 2023
1:18
Strategies to overcome cultural factors and perceptions about MS care
Mitzi Joi Williams • 22 May 2023
1:42
NMOSDCopilot: smartphone-based digital biomarkers
Michael Levy • 26 Apr 2023
8:25
Update on the role of the microbiome in MS
Anne-Katrin Pröbstel • 26 Apr 2023
1:05
MS highlights at AAN: BTK inhibitors
Augusto Miravalle • 5 May 2023
4:31
Next steps in treating MS through gut microbiota
Anne-Katrin Pröbstel • 26 Apr 2023
1:44
Predictors of conversion from positive to negative MOG antibody status
Michael Levy • 26 Apr 2023
5:04
IgA: a new biomarker of demyelinating disease
Anne-Katrin Pröbstel • 26 Apr 2023
1:59
Using biomarkers to tailor treatment options for MS
Augusto Miravalle • 5 May 2023
3:22
Efficacy subgroup analyses from the Phase III CHAMPION-NMOSD trial
Michael Levy • 26 Apr 2023
4:40
MOG-IgA characterizes a subgroup of patients with central nervous system demyelination
Anne-Katrin Pröbstel • 26 Apr 2023
1:02
The future of ravulizumab in NMOSD
Michael Levy • 26 Apr 2023
The content of VJNeurology is intended for healthcare professionals